糖尿病治療薬の世界市場:インスリン、DPP-4、スルホニルウレア、αグルコシダーゼ阻害剤、チアゾリジンジオン、SGLT2阻害薬、ビグアニド等

◆英語タイトル:Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025
◆商品コード:VGAIN5050814
◆発行会社(調査会社):visiongain
◆発行日:2015年5月
◆ページ数:240
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥257,257見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥428,857見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥714,857見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、糖尿病治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・糖尿病治療薬の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・糖尿病治療薬の世界市場:セグメント別市場分析
 (インスリン、DPP-4、スルホニルウレア、αグルコシダーゼ阻害剤、チアゾリジンジオン、SGLT2阻害薬、GLP-1受容体作動薬、ビグアニド)
・地域別市場分析、市場規模予測
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Treating diabetes – benefit your influence by finding new R&D trends and sales prospects
Discover the future of antidiabetic medicines. For those treatments, now get new revenue predictions, also exploring research and development. Discover diabetes market size and business potentials. And assess results, trends, technologies, therapies and opportunities.

Visiongain’s updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You stay ahead in data on treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.

See what’s possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines’ predicted revenue.

Forecasts to 2025 and other analyses explain and predict the diabetes treatment market
Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.

That study also shows 90 tables, 91 charts and two interviews. Our work’s purpose is to predict that industry’s future, helping your research, analyses and decisions. See there how you can benefit your reputation for commercial insight, also helping your influence.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities lie.

Though no such study covers everything on treating high blood sugar, the following sections show how our new investigation benefits your work.

Forecasting of that world market and its segments – what does the future hold?
What are the secrets of that industry’s progress? Where’s it heading? Discover in our report overall world revenue prediction to 2025 for antidiabetic pharmaceuticals, with discussions.

Also find individual revenue forecasts to 2025 for nine therapeutic submarkets at world level:
• Human insulins and analogues
• Dipeptidyl peptidase-4 inhibitors (DPP-4)
• Biguanides
• Glucagon-like peptide-1 receptor agonists (GLP-1)
• Sulfonylureas.

And these treatment categories:
• Thiazolidinediones
• Alpha-glucosidase inhibitors
• Meglitinides
• Sodium-glucose co-transporter-2 inhibitors (SGLT2)
• Other agents (grouped).

There assess outlooks for revenue expansion, hearing where you can profit. Find the diabetes market size from 2015. You investigate competition and rising sales. And you examine technological, clinical and commercial possibilities.

Also find top medicines’ revenue potentials.


Predictions of leading products’ sales – see what’s possible, where you can gain
How will individual drugs for elevated blood sugar perform to 2025 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents:
• Lantus
• Januvia
• NovoLog and NovoMix
• Levemir
• Humalog
• Victoza
• Janumet
• Humulin.

There you find drugs and years with highest predicted sales. You also examine competitors. So discover what’s happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.

That work also gives geographical sales predictions.

National markets – what outlooks for treatment demand and revenues?
In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2015 to 2025. See where, how and what’s possible.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy and Spain (EU5)
• BRIC nations – Brazil, Russia, India and China.

There you explore progress, needs and opportunities. What events change that market and outlooks for payers and patients? Our work shows you, discussing trends and demands.

Events affecting developers, producers and sellers of those metabolic treatments
That report also explains issues, forces and events affecting the antidiabetics industry and market from 2015, including these influences:
• Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates
• Governmental investment and collaboration between pharmaceutical companies
• Combination therapies for type 2 diabetes
• Competition from biosimilars and generic drugs – approvals and product launches.

And these issues, among others:
• Disease incidence and prevalence
• Risk factors – obesity and pre-diabetes, related metabolic conditions
• Drug delivery – technologies for introducing insulin and oral drugs
• New classes of antidiabetic medications and regulatory challenges
• Type 1 diabetes vaccine – new treatment approaches, including disease prevention.

Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you investigate what stimulates and restrains that biopharma, affecting its results. Also see prospects for small-molecule therapies.

Analysis of firms and potential for rising sales – what overall revenues possible?
What happens next? Our study predicts that world market will rise to $72.6bn in 2019, with high, expanding revenues from 2015 to 2025. See what’s possible.

Our analysis covers organisations shaping that industry:
• Novo Nordisk
• Eli Lilly
• Novartis
• AstraZeneca
• Merck & Co.

Also investigate these leading companies, among other firms, including specialists in metabolic disorders:
• Boehringer Ingelheim
• Takeda
• Sanofi
• Bayer
• Pfizer.

And gain interviews with two other authorities on diabetes treatments. Our survey explores issues affecting that healthcare industry’s present and future.

From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.

【レポートの目次】

1. Report Overview
1.1 Introduction to that Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered
1.7 Who is This Study For?
1.8 Research and Analysis Methods
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Global Diabetes Drug Market: Introduction
2.1 World Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes

3. The World Diabetes Drugs Market, 2015-2025
3.1 The World Diabetes Drug Market, 2014
3.1.1 Diabetes Treatment Market by Drug Class, 2014
3.1.2 Top Selling Diabetes Drugs, 2014
3.1.3 Generic Anti Diabetes Drugs, 2014
3.1.4 Top 10 Diabetes Drug Producers, 2014
3.2 World Diabetes Drugs Market: Revenue Forecast, 2015-2025

4. Human Insulin and Analogues Market, 2015-2025
4.1 Insulin and Insulin Analogues Drugs, 2014
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2015-2025
4.3 Insulin and Insulin Analogues: Market Trends, 2015-2025
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2015-2025
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast,
2015-2025
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2015-2025
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast,
2015-2025
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2015-2025
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast,
2015-2025
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2015-2025

5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2015-2025
5.1 DPP-4 Market, 2014
5.2 DPP-4 Inhibitors Revenue Forecast, 2015-2025
5.3 Januvia (Sitagliptin; Merck & Co.): Revenue Forecast, 2015-2025
5.4 Janumet (Sitagliptin and Metformin; Merck & Co.): Revenue Forecast, 2015-2025
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2015-2025
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2015-2025
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2015-2025
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2015-2025

6. Sulfonylureas Market, 2015-2025
6.1 Sulfonylureas Market, 2014
6.2 Sulfonylureas: Revenue Forecast, 2015-2025
6.3 Sulfonylureas: Market Trends 2015-2025
6.3.1 New Opportunities for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2015-2025
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2015-2025
6.6 Glucotrol (Glipizide; Pfizer): Revenue Forecast, 2015-2025

7. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, 2015-2025
7.1 GLP-1 Receptor Agonists Market, 2014
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2015-2025
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2015-2025
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost the Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2015-2025
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025

8. Alpha-glucosidase Inhibitors Market, 2015-2025
8.1 Alpha-glucosidase Inhibitors Market, 2014
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2015-2025
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2015-2025
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2015-2025
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2015-2025
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2015-2025

9. Meglitinides Market, 2015-2025
9.1 Meglitinides Market, 2014
9.2 Meglitinides: Revenue Forecast, 2015-2025
9.2.1 Meglitinides: Market Trends, 2015-2025
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2015-2025
9.4 Sarlix (Nateglinide; Novartis): Revenue Forecast, 2015-2025
9.5 Glufast (Acarbose; Bayer): Revenue Forecast, 2015-2025

10. Thiazolidinediones Market, 2014
10.1 Thiazolidinediones Market Overview, 2014

11. Sodium-glucose Co-transporter-2 (SGLT2) Inhibitors Market, 2015-2025
11.1 SGLT2 Inhibitors Market, 2014
11.2 SGLT2 Revenue Forecast, 2015-2025
11.2.1 SGLT2 Market Trends, 2015-2025
11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2015-2025
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2015-2025
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2015-2025

12. Biguanides Market, 2015-2025
12.1 Biguanides Market, 2014
12.2 Biguanides: Revenue Forecast, 2015-2025
12.2.1 Biguanides: Market Trends, 2015-2025
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck & Co): Revenue Forecast, 2015-2025
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2015-2025
12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2015-2025

13. National Markets for Diabetes Drugs, 2015-2025
13.1 Leading National Markets for Diabetes Drugs, 2014
13.2 Leading National Diabetes Drugs Market: Revenue Forecast,
2015-2025
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2015-2025
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast 2015-2025
13.4.1 Increased Governmental Investment Will Drive Market Growth
13.4.2 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.3 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2014
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market: Revenue Forecasts, 2015-2025
13.5.1.1 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2015-2025
13.5.1.2 Great Standard of Care and Regulatory Reforms in France – Revenue Forecast 2015-2025
13.5.1.3 Austerity Measures in Spain Discourage Companies – Revenue Forecast 2015-2025
13.5.1.4 UK: High Burden of Diabetes Costs on the UK NHS
13.5.1.5 Italy: Stable Market with Good Standards of Care – Revenue Forecast, 2015-2025
13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2015-2025
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2015-2025.
13.7.1 Focus on the Rural Population
13.8 Introduction of Novel Therapies in the Russian Federation – Revenue Forecast, 2015-2025
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2015-2025
13.9.1 Localized Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives will Increase Market Potential

14. Diabetes Drug Market R&D Pipeline, 2015
14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015
14.1.1 Novo Nordisk
14.1.2 Eli Lilly & Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (LY2963016 Eli Lilly and Boehringer Ingelheim): US Approval Delay May Trigger High Revenues
14.2.2 Insulin Glargine (U300 Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin. Will it Reach $1bn Sales?
14.3 Human Insulins and Analogues: Pipeline Developments, 2015
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 Basal Insulin Peglispro-BIL (Eli Lilly): Holding Promise – What Will More Testing Bring?
14.3.3 MK-1293 (Merck & Co. and Biogen Idec): Another Biosimilar of Lantus on the Way
14.3.4 OG217SC (Novo Nordisk)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex) Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck & Co.)
14.4.3 ARI-2243 (Arisaph)
14.5 GLP-1: New Approvals and Pipeline, 2015
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Does it have the Potential to Reach Blockbuster Status?
14.5.2 Tanzeum (Albiglutide; GSK)
14.5.3 Semaglutide (NN9535; Novo Nordisk)
14.5.4 Xultophy (formerly IDegLira; Novo Nordisk)
14.5.5 ITC650 (Intarcia Therapeutics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2015
14.6.1 Suglat (Ipragliflozin; Astellas Pharma/Kotobuki)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 Lusefi (Luseogliflozin; Taisho Pharmaceutical)
14.7 Other Anti Diabetes Drugs: Pipeline Developments, 2015
14.7.1 DM199 (DiaMedica)
14.7.2 DiaPep277 (Andromeda Biotech)
14.7.3 Glucokinase Activators
14.7.4 ZYGK1 (Zydus Cadila Healthcare)
14.7.5 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)

15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2015-2025
15.1 SWOT Analysis of the Diabetes Drug Market, 2015-2025
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to Copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers – Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2015-2025
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues

16. Research Interviews
16.1 Interview with an Academic Involved in Diabetes R&D
16.1.1 The Insulin Drug Market
16.1.2 Novel Delivery Technologies
16.1.3 Future Developments and Market Prospects
16.2 Interview with James Anderson, Generex Biotechnology Corporation
16.2.1 The Current Diabetes Drug Market
16.2.2 Generex’s Oral-lyn™ Product and Buccal Drug Delivery

17. Conclusions from the Research and Analysis
17.1 The Diabetes Market – Trends Shaping Those Treatments
17.2 Outlook of the Worlds Diabetes Drug Industry, 2015-2025
17.2.1 Insulin Will Continue to Dominate the Market
17.3 Regional Outlooks for That Market, 2015-2025
17.4 Future Opportunities

List of Tables
Table 1.1 Leading National Diabetes Drugs Market Forecast, 2015-2025 ($bn, AGR %), 2014-2025
Table 1.2 Foreign Currency Exchange Rates Utilised: Exchange Rate to $USD, 2014
Table 2.1 Types of Injectable Insulin, 2015
Table 2.2 Oral Drug Classes for Type 2 Diabetes, 2015
Table 2.3 Other Injectable Drugs for Type 2 Diabetes, 2015
Table 2.4 Combination Drug Therapies for Type 2 Diabetes, 2015
Table 3.1 World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2014
Table 3.2 World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drug Class, 2014
Table 3.3 Top 10 Diabetes Drugs Sales ($m), 2014
Table 3.4 Top 3 Human Insulin Producers: Sales ($m), 2014
Table 3.5 Top 10 Diabetes Drugs Producers: Sales ($m), 2014
Table 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn) by Drug Class, 2014-2019
Table 3.7 World Diabetes Drugs Market: Revenue Forecasts ($bn) by Drug Class,
2020-2025
Table 4.1 Human Insulins and Analogues: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 4.2 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 4.3 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 4.4 Top 3 Human Insulin Producers: Sales ($m), 2014
Table 4.5 Lantus: Drug Revenue Forecast ($bn), 2014-2025
Table 4.6 NovoLog: Drug Revenue Forecast ($bn), 2014-2025
Table 4.7 Humalog: Drug Revenue Forecast ($bn), 2014-2025
Table 4.8 Levemir: Revenue Forecast ($bn), 2014-2025
Table 4.9 Human Insulins Novo Nordisk: Revenue Forecast ($bn), 2014-2025
Table 4.10 NovoMix: Revenue Forecast ($bn), 2014-2025
Table 4.11 Humulin: Revenue Forecast ($bn), 2014-2025
Table 5.1 DPP-4 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 5.2 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 5.3 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 5.4 Januvia: Revenue Forecast ($bn), 2014-2025
Table 5.5 Janumet: Revenue Forecast ($bn), 2014-2025
Table 5.6 Galvus: Revenue Forecast ($bn), 2014-2025
Table 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025
Table 5.8 Nesina: Revenue Forecast ($bn), 2014-2025
Table 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025
Table 6.1 Sulfonylureas: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 6.2 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 6.3 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025
Table 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025
Table 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025
Table 7.1 GLP-1: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 7.2 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 7.3 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 7.4 Victoza: Revenue Forecast ($bn), 2014-2025
Table 7.5 Byetta: Revenue Forecast ($bn), 2014-2025
Table 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025
Table 8.1 Alpha-glucosidase Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 8.2 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 8.3 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025
Table 8.5 Basen: Revenue Forecast ($bn), 2014-2025
Table 8.6 Glyset: Revenue Forecast ($bn), 2014-2025
Table 9.1 Meglitinides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 9.2 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 9.3 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 9.4 Prandin: Revenue Forecast ($bn), 2014-2025
Table 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025
Table 9.6 Glufast: Revenue Forecast ($bn), 2014-2025
Table 10.1 Thiazolidinediones: Revenues ($bn), 2014
Table 11.1 SGLT2 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 11.2 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 11.3 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 11.4 Invokana: Revenue Forecast ($bn), 2014-2025
Table 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025
Table 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025
Table 12.1 Biguanides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
Table 12.2 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
Table 12.3 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
Table 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025
Table 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025
Table 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025
Table 13.1 The Global Diabetes Drugs Market: Revenues ($bn) and Market Shares (%) by Region, 2014
Table 13.2 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2014-2019
Table 13.3 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2020-2025
Table 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Table 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Table 13.6 EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($bn) and Market Share (%) by Country, 2014
Table 13.7 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts ($bn), 2014-2019
Table 13.8 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2020-2025
Table 13.9 Germany: Revenue Forecast ($bn), 2014-2025
Table 13.10 France: Revenue Forecast ($bn), 2014-2025
Table 13.11 Spain: Revenue Forecast ($bn), 2014-2025
Table 13.12 United Kingdom: Revenue Forecast ($bn), 2014-2025
Table 13.13 Italy: Revenue Forecast ($bn), 2014-2025
Table 13.14 China: Revenue Forecast ($bn), 2014-2025
Table 13.15 India: Revenue Forecast ($bn), 2014-2025
Table 13.16 Russia: Revenue Forecast ($bn), 2014-2025
Table 13.17 Brazil: Revenue Forecast ($bn), 2014-2025
Table 14.1 FDA Approved Anti Diabetes Drugs, 2014
Table 14.2 Expected FDA Approvals for Anti Diabetes Drugs, 2015 and 2016
Table 17.1 The Global Diabetes Drugs Market: Overall Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025
Table 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) and Market Shares (%) in Leading Regional Markets, 2014, 2019 and 2025
Table 17.3 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025

List of Figures
Figure 2.1 Diabetes Drugs Market Segmentation Overview, 2015
Figure 2.2 Diabetes Drugs Sub-market Segmentation, 2015
Figure 2.3 Diabetes Types and Classification, 2015
Figure 2.4 Diabetes Causes, 2015
Figure 2.5 Diabetes Regional Prevalence (population million), 2014
Figure 2.6 Diabetes Prevalence and Undetected Prevalence (%) by Region, 2014
Figure 2.7 World Number of Diabetics (population million), 2014-2025
Figure 3.1 World Diabetes Drugs Market: Market Share (%) by type of Medication, 2014
Figure 3.2 World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2014
Figure 3.3 Top 10 Diabetes Drugs by Market Share (%), 2014
Figure 3.4 Top 10 Diabetes Drugs Producers vs Other Manufacturers: Market Share (%), 2014
Figure 3.5 Top 10 Diabetes Drugs Producers: Market Share (%), 2014
Figure 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2015
Figure 4.1 Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2014
Figure 4.2 Human Insulins and Analogues: Revenue Forecast ($bn), 2014-2025
Figure 4.3 Lantus: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.4 NovoLog: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.5 Humalog: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.6 Levemir: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.7 Human Insulins Novo: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.8 NovoMix: Drug Revenue Forecast ($bn), 2014-2025
Figure 4.9 Humulin: Drug Revenue Forecast ($bn), 2014-2025
Figure 5.1 DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2014
Figure 5.2 DPP-4 Inhibitors: Sales ($bn) for Leading Drugs, 2014
Figure 5.3 DPP-4 Inhibitors: Revenue Forecast ($bn), 2014-2025
Figure 5.4 Januvia: Revenue Forecast ($bn), 2014-2025
Figure 5.5 Janumet: Revenue Forecast ($bn), 2014-2025
Figure 5.6 Galvus: Revenue Forecast ($bn), 2014-2025
Figure 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025
Figure 5.8 Nesina: Revenue Forecast ($bn), 2014-2025
Figure 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025
Figure 6.1 Sulfonylureas: Market Shares (%) for Leading Drugs, 2014
Figure 6.2 Sulfonylureas: Sales ($bn) for Leading Drugs, 2014
Figure 6.3 Sulfonylureas: Revenue Forecast ($bn), 2014-2025
Figure 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025
Figure 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025
Figure 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025
Figure 7.1 GLP-1: Market Shares (%) for Leading Drugs, 2014
Figure 7.2 GLP-1: Sales ($bn) for Leading Drugs, 2014
Figure 7.3 GLP-1 Receptor Agonists: Revenue Forecast ($bn), 2014-2025
Figure 7.4 Victoza: Revenue Forecast ($bn), 2014-2025
Figure 7.5 Byetta: Revenue Forecast ($bn), 2014-2025
Figure 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025
Figure 8.1 Alpha-glucosidase Inhibitors: Revenue Sales ($bn), 2014
Figure 8.2 Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2014
Figure 8.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($bn), 2014-2025
Figure 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025
Figure 8.5 Basen: Revenue Forecast ($bn), 2014-2025
Figure 8.6 Glyset: Revenue Forecast ($bn), 2014-2025
Figure 9.1 Meglitinides: Market Shares (%) for Leading Drugs, 2014
Figure 9.2 Meglitinides: Market Sales ($bn) for Leading Drugs, 2014
Figure 9.3 Meglitinides: Revenue Forecast ($bn), 2014-2025
Figure 9.4 Prandin: Revenue Forecast ($bn), 2014-2025
Figure 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025
Figure 9.6 Glufast: Revenue Forecast ($bn), 2014-2025
Figure 10.1 Thiazolidinediones: Sales ($bn), 2014
Figure 11.1 SGLT2 Inhibitors: Sales ($bn) for Leading Drugs, 2014
Figure 11.2 SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2014
Figure 11.3 SGLT2 Inhibitors: Revenue Forecast ($bn), 2014-2025
Figure 11.4 Invokana: Revenue Forecast ($bn), 2014-2025
Figure 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025
Figure 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025
Figure 12.1 Biguanides: Market Shares (%) for Leading Drugs, 2014
Figure 12.2 Biguanides: Sales ($bn) for Leading Drugs, 2014
Figure 12.3 Biguanides: Revenue Forecast ($bn), 2014-2025
Figure 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025
Figure 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025
Figure 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025
Figure 13.1 The Global Diabetes Drugs Market: Revenues ($bn) by Region, 2014
Figure 13.2 Top 3 Global Markets vs BRIC Countries: Market Shares (%), 2014
Figure 13.3 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2014
Figure 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Figure 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
Figure 13.6 EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($bn) by Country, 2014
Figure 13.7 EU5 (Germany, France, UK, Italy, Spain) Countries: Market Shares (%) by Country, 2014
Figure 13.8 EU5 (Germany, France, UK, Italy, Spain) Countries Market Global and EU5 Market Share (%), 2014
Figure 13.9 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2014-2025
Figure 13.10 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($bn), 2014-2025
Figure 13.11 Germany: Revenue Forecast ($bn), 2014-2025
Figure 13.12 France: Revenue Forecast ($bn), 2014-2025
Figure 13.13 Spain: Revenue Forecast ($bn), 2014-2025
Figure 13.14 United Kingdom: Revenue Forecast ($bn), 2014-2025
Figure 13.15 Italy: Revenue Forecast ($bn), 2014-2025
Figure 13.16 China: Revenue Forecast ($bn), 2014-2025
Figure 13.17 India: Revenue Forecast ($bn), 2014-2025
Figure 13.18 Russia: Revenue Forecast ($bn), 2014-2025
Figure 13.19 Brazil: Revenue Forecast ($bn), 2014-2025
Figure 15.1 SWOT Analysis of the World Diabetes Drugs Market, 2015-2025
Figure 15.2 STEP Analysis of the World Diabetes Drugs Market, 2015-2025
Figure 17.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025
Figure 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025

【掲載企業】

Actavis
Alphapharm
American Diabetes Association
Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
Andromeda Biotech
Arisaph
Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)
Astellas Pharma
AstraZeneca
Bayer
Biocon
Blue Cross
Bristol-Myers Squibb
Biogen Idec
Boehringer Ingelheim
Boston Therapeutics
Chugai Pharmaceutical
Diabetes UK
DiaMedica
Diamyd Medical
Eisai
Eli Lilly
European Medicines Agency (EMA)
Express Scripts
Food and Drug Administration (US FDA)
Franco-Indian Pharmaceuticals
Furiex Pharmaceuticals
Genentech
Generex Biotechnology Corporation
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Google
Human Genome Sciences
Intarcia
International Diabetes Federation (IDF)
Janssen (subsidiary of J&J)
Johnson & Johnson (J&J)
Lupin
Kissei Pharmaceuticals
Kotobuki Pharma
Kowa
MannKind Corporation
Mascot Health Series
Merck & Co.
Merck Serono
Ministry of Health (MoH, Germany)
Ministry of Health, Labour and Welfare (MHLW, Japan)
MSD KK (Asian subsidiary of Merck & Co.)
Mylan
National Health Service (NHS, UK)
National Institute of Health and Clinical Excellence (NICE, UK)
Novartis
Novo Nordisk
Ono Pharmaceuticals
Oramed Pharmaceuticals
Patheon
Pfizer
Ranbaxy Laboratories
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus (bought by Salix Pharmaceuticals)
Servier
Shantha Biotechnics (acquired by Sanofi)
Shionogi Pharmaceuticals
Shreya Life Sciences
Stanford University School of Medicine
Sun Pharma
Takeda
Taisho Pharmaceutical
Teva Pharmaceutical Industries
Transdermal Specialities
United States Diabetes Prevention Program (DPP)
World Health Organization (WHO)
Yabao Pharmaceutical
Zydus Cadila

【レポートのキーワード】

糖尿病、治療薬、インスリン、DPP-4、スルホニルウレア、αグルコシダーゼ阻害剤、チアゾリジンジオン、SGLT2阻害薬、GLP-1受容体作動薬、ビグアニド、糖尿病治療

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[糖尿病治療薬の世界市場:インスリン、DPP-4、スルホニルウレア、αグルコシダーゼ阻害剤、チアゾリジンジオン、SGLT2阻害薬、ビグアニド等]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月11日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆